Karyopharm Therapeutics Inc. - KPTI
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| May 15, 2026 | SCHEDULE 13G | Ikarian Capital, LLC | 0.0% | 0 | View |
| May 15, 2026 | SCHEDULE 13G | Neil Shahrestani | 0.0% | 0 | View |
| May 15, 2026 | SCHEDULE 13G | ACORN BIOVENTURES, L.P. | 2.8% | 637,608 | View |
| May 15, 2026 | SCHEDULE 13G | ACORN CAPITAL ADVISORS GP, LLC | 2.8% | 637,608 | View |
| May 15, 2026 | SCHEDULE 13G | ACORN BIOVENTURES 2, L.P. | 3.9% | 880,505 | View |
| May 15, 2026 | SCHEDULE 13G | Acorn Capital Advisors GP 2, LLC | 3.9% | 880,505 | View |
| May 15, 2026 | SCHEDULE 13G | Anders Hove | 6.7% | 1,518,113 | View |
| May 14, 2026 | SCHEDULE 13G/A | Affinity Asset Advisors, LLC | 8.6% | 2,073,517 | View |
| May 14, 2026 | SCHEDULE 13G/A | Michael Cho | 8.6% | 2,073,517 | View |
| May 13, 2026 | SCHEDULE 13G | Adage Capital Management, L.P. | 8.08% | 1,821,736 | View |
| May 13, 2026 | SCHEDULE 13G | Robert Atchinson | 8.08% | 1,821,736 | View |
| May 13, 2026 | SCHEDULE 13G | Phillip Gross | 8.08% | 1,821,736 | View |
| May 12, 2026 | SCHEDULE 13G | THE GOLDMAN SACHS GROUP, INC. | 5.1% | 991,364 | View |
| May 12, 2026 | SCHEDULE 13G | GOLDMAN SACHS & CO. LLC | 5.1% | 991,364 | View |
| May 11, 2026 | SCHEDULE 13G/A | Opaleye Management Inc. | 2.67% | 619,089 | View |
| May 11, 2026 | SCHEDULE 13G/A | Opaleye, L.P. | 2.67% | 619,089 | View |
| May 11, 2026 | SCHEDULE 13G/A | James Silverman | 2.67% | 619,089 | View |
| Apr 13, 2026 | SCHEDULE 13G/A | Integrated Core Strategies (US) LLC | 1.9% | 423,982 | View |
| Apr 13, 2026 | SCHEDULE 13G/A | Millennium Management LLC | 2.3% | 511,571 | View |
| Apr 13, 2026 | SCHEDULE 13G/A | Millennium Group Management LLC | 2.3% | 511,571 | View |
| Apr 13, 2026 | SCHEDULE 13G/A | Israel A. Englander | 2.3% | 511,571 | View |
| Apr 02, 2026 | SCHEDULE 13G | Commodore Capital LP | 9.9% | 1,950,000 | View |
| Apr 02, 2026 | SCHEDULE 13G | Commodore Capital Master LP | 9.9% | 1,950,000 | View |
| Apr 02, 2026 | SCHEDULE 13G | Robert Egen Atkinson | 9.9% | 1,950,000 | View |
| Apr 02, 2026 | SCHEDULE 13G | Michael Kramarz | 9.9% | 1,950,000 | View |
| Apr 02, 2026 | SCHEDULE 13G | RA Capital Management, L.P. | 9.9% | 2,078,913 | View |
| Apr 02, 2026 | SCHEDULE 13G | Peter Kolchinsky | 9.9% | 2,078,913 | View |
| Apr 02, 2026 | SCHEDULE 13G | Rajeev Shah | 9.9% | 2,078,913 | View |
| Apr 02, 2026 | SCHEDULE 13G | RA Capital Healthcare Fund, L.P. | 9.9% | 2,078,913 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | T. Rowe Price Investment Management, Inc. | 11.8% | 2,244,421 | View |
| Feb 12, 2026 | SCHEDULE 13G/A | Adage Capital Management, L.P. | 2.38% | 436,736 | View |
| Feb 12, 2026 | SCHEDULE 13G/A | Robert Atchinson | 2.38% | 436,736 | View |
| Feb 12, 2026 | SCHEDULE 13G/A | Phillip Gross | 2.38% | 436,736 | View |
| Feb 10, 2026 | SCHEDULE 13G | Integrated Core Strategies (US) LLC | 5.4% | 997,577 | View |
| Feb 10, 2026 | SCHEDULE 13G | Millennium Management LLC | 5.5% | 1,008,662 | View |
| Feb 10, 2026 | SCHEDULE 13G | Millennium Group Management LLC | 5.5% | 1,008,662 | View |
| Feb 10, 2026 | SCHEDULE 13G | Israel A. Englander | 5.5% | 1,008,662 | View |
| Jan 29, 2026 | SCHEDULE 13G/A | Affinity Asset Advisors, LLC | 8.6% | 1,713,092 | View |
| Jan 29, 2026 | SCHEDULE 13G/A | Michael Cho | 8.6% | 1,713,092 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.